DXCM News and Press, DexCom Inc. From 01/09/23

Glucose monitoring company DexCom ( NASDAQ: DXCM ) expects Q4 revenue to be at least $815M, an increase of 17% Y/Y on a reported basis and 20% on an organic basis. The Q4 revenue consensus stands at $808M. U.S. segment's revenue is expected to be ~$606M, up 17% ...

DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be at least $815 million, an increase of 17% over the fourth quarter of 2021 ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the appointment of Teri Lawver to the newly created role of chief commercial officer. In this role, Ms. Lawver will oversee the global commercial organization with...

Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 41 st annual J.P. Morgan Healthcare Conference on January 9, 2023. The live presentation is scheduled to begin at approximately 2:15...

Summary DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting margins. Some competitive risks. For further details see:...

Summary Down 40%+ this year, EW is now trading at levels not seen in years. I believe the sell-off is unjust, and investors over the next few months will benefit immensely. This article will cover why past performance almost guarantees continued success. Introduction W...

Looking to add to your basket of stocks before the year is out? Even a relatively modest amount of investment capital like $1,500 can help you build a meaningful starter position in stocks you love. If you're hunting for great companies to add to your portfolio before 2023 hits, here are two ...

Growth stocks aren't all the same, and it's fair to say that some may not recover from the period of volatility investors have witnessed over the past year. However, companies with strong businesses and industry tailwinds that can drive growth forward in the future are still abundant, even in the...

New Digital Diabetes Care Program combines Dexcom G6 real-time continuous glucose monitoring (rtCGM) with enhanced virtual diabetes management support services Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (rtCGM), announced today its partnership with Gr...